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Polarity of -galactosidase A uptake by renal tubule cells. functionality of the endocytosed AGA should lend itself
Background. Congenital absence of -galactosidase in Fabry well to protein therapy for this disorder. Although the
disease leads eventually to renal failure. Fabry disease is an AGA enzyme has been isolated and purified, and prelim-attractive candidate for gene therapy, but uptake mechanisms
inary reports of protein therapy in animals and humansof the enzyme must be understood for it to be used in treating
patients with Fabry disease. are very promising, the production of recombinant pro-
Methods. Immortalized human renal epithelial cells from tein on a large scale remains extremely costly and will
three regions of the tubule were grown in culture on collagen- require frequent infusions to achieve a prolonged effectcoated Transwell filters and were incubated with recombinant
given the short half-life of the enzyme.-galactosidase protein placed at either the luminal or basolat-
Fabry disease is an excellent model for gene therapyeral side of the cells. Uptake into cells was measured, and
kinetic studies were performed. Blocking experiments were for several reasons. First, the gene for Fabry disease has
done with mannose 6-phosphate. been cloned, and AGA production, secretion, absorp-
Results. Uptake from the basolateral side of the filters pre-
tion, and function have been extensively studied. Second,dominated in all three cell types. Only in distal tubule cells
there is an AGA-knockout mouse model [4], which de-was mannose 6-phosphate able to block uptake to any degree.
The kinetic data reveal a high Km for both luminal and basolat- velops a reasonable approximation of the human disease
eral cell surfaces. on a histologic level, that will support preliminary gene
Conclusions. These data suggest that to correct the renal therapy studies prior to potential primate and humanphenotype in Fabry disease, high levels of the enzyme will be
studies. Finally, AGA is continuously secreted and endo-need to be delivered to kidney cells. This will likely best be
cytosed distally from its site of production, where it canachieved with local administration of a vector containing the
transgene directly to the kidney. continue the catabolism of glycosphingolipid. Thus, the
introduction of a vector constitutively producing the
AGA protein would theoretically be able to ameliorate
Fabry disease is an X-linked lysosomal storage disease the Fabry phenotype both in the cells in which the recom-
in which deficiency of the lysosomal hydrolase -galac- binant AGA gene is expressed and at sites distal from
tosidase A (AGA) leads to deposits of the glycosphingo- AGA production site via the secretion-endocytosis path-
lipid globotriaosylceramide (GL-3) in a number of tissues, way. Recently, a gene therapy study has been reported
including brain, heart, and kidney [1]. The ultimate renal in which a recombinant adenoviral vector expressing the
manifestation of this disease is a slowly progressive and AGA gene was infused through a tail vein into Fabry
inexorable decline in renal function, leading to end-stage knockout mice [5]. However, the resulting transient ex-
renal disease by the fourth or fifth decade. Currently, pression of AGA was not completely successful: AGA
there is no proven treatment for the disease, with patients eliminated GL-3 accumulation in every organ except the
faced with the choice of dialysis or a possible transplant. kidney, where only a 50 to 75% decrease was observed
In normal metabolism, AGA is produced by a wide vari-
despite significant circulating levels of AGA in the
ety of cells and organs. In addition, a significant portion
plasma. In addition, renal GL-3 reaccumulated moreof the enzyme is secreted and endocytosed distally into
rapidly than that in other organs.lysosomes, where it is active and serves the function of
The studies described in this article were designedGL-3 catabolism [2]. It has been shown that the majority
to assess whether the resistance of the kidney to theof secreted AGA is re-endocytosed distally after binding
circulating levels of AGA achieved in the adenovirusto the mannose 6-phosphate (M6-P) receptor [3]. The
gene therapy trial was the result of limited uptake of
AGA by renal tubule cells. In addition, AGA uptake
Key words: Fabry disease, gene therapy, adeno-associated virus. from the apical and basolateral cell surfaces was com-
pared, as predominance of either apical or basolateral 2002 by the International Society of Nephrology
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Fig. 2. Inhibition by M6-P of AGA uptake from the basolateral surface
Fig. 1. AGA uptake from either the luminal (open bar) or basolateral of NHCT cells. Control, solid bar; M6-P, open bar.
(solid bar) side of the epithelial cells plated on Transwell filters. Uptake
in proximal tubule cells (NHPST), thick ascending limb cells (NHTAL),
and cortical collecting duct cells (NHCT) was always greater from the
basolateral cell surface.
filters at concentrations of 83 to 1.66 g/mL with PBS
used as a control. After one hour, aliquots of luminal
and basolateral media were removed, the cells were
uptake of the protein might dictate the best route for rinsed twice with PBS and lysed, and the AGA activity
viral vector delivery. was assayed as described previously in this article. In all
studies, the integrity of the cell monolayer on the filter
was assayed by both light microscopy and the ability ofMETHODS
the monolayer to prevent movement of AGA across theThree renal cell types were used in this study: normal
filters (less than 10% transmembrane diffusion/transporthuman proximal straight tubule (NHPST), thick as-
from the AGA-exposed side of the filter to the unex-cending limb (NHTAL), and collecting tubule (NHCT)
posed side). The affinity (Km) and maximal velocitycells. The cells were conditionally immortalized with
(Vmax) for AGA uptake were then determined using thetemperature-sensitive SV40 T antigen and were grown
Lineweaver Burke formula.in defined, cell-type-specific media on collagen-coated
Transwell filters at 32C. At confluence, cells were placed
at 37C for five to seven days to promote maximal differ- RESULTS
entiation. When grown in this manner, these cells express
In NHPST, NHTAL, and NHCT, there was significantcharacteristic tubule segment-specific markers that are
uptake of AGA to more than 20-fold above normal basalpolarized to the appropriate cell surfaces and manifest
levels. In addition, basolateral uptake was twofold totubule segment specific transport properties [6]. In initial
sevenfold greater than luminal entry, as shown in Figurestudies, recombinant AGA was added to the luminal or
1. Despite the fact that the M-6P receptor has beenbasolateral cell surface (70 g/mL) in the presence or
thought to be the predominant receptor for AGA up-absence of M6-P (5 mmol/L). After a 24-hour incubation
take, other receptors likely play a role in uptake. Thisat 37C, aliquots of luminal and basolateral media were
is demonstrated by the fact that only at the basolateralremoved and frozen at 20C until assayed for AGA
side of NHCT cells did the putative receptor for M6-Pactivity. Cells were washed twice in phosphate-buffered
achieve any significant blockade, as shown in Figure 2.saline (PBS), pH 7.4, and then lysed in citrate phosphate
Surprisingly, in the NHCT cells, inhibition of basolateralbuffer, pH 6.5, containing 0.1% Triton X-100, and the
uptake only achieved 36% inhibition, suggesting thatlysate was frozen at 20C until assayed for AGA activ-
even in this case there might be alternative mechanismsity. AGA activity was determined using the fluorescence
of AGA entry. Of note, there was minimal detection ofof the artificial substrate 4-methylumbeliferyl -D-galac-
recombinant AGA in the chamber opposite that in whichtopyranoside [7].
the recombinant AGA was placed, with mean transepi-In subsequent studies of the kinetics of AGA uptake,
thelial transport of 10%. This indicates that the cellnormal human collecting tubule cells were plated on
monolayers were complete and that AGA uptake accu-collagen-coated Transwell filters as described previously
rately represents the transport properties of each of thein this article. Recombinant AGA diluted in PBS was
placed in the lumen or bath side of the collagen-coated cell surfaces exposed to AGA.
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Fig. 3. A Lineweaver plot of AGA uptake from the luminal
(solid circles) or basolateral (open circles) surfaces of NHCT
cells. The calculated x intercepts of the linear regression
lines for the data represent 1/Km for AGA uptake.
The uptake kinetic studies, as depicted in a typical transient gene expression [8]. Retroviral vectors require
dividing cells to achieve expression, which means thereexperiment in Figure 3, demonstrate a relatively high
must be renal injury in order to be effective. Further-Km of 14.1  7.9 g/mL for the basolateral cell surface
more, despite integration into the host genome, expres-in two studies and a Vmax of 887  541. The luminal
sion has been transient [9]. Adenoviral vectors have beenuptake studies had a mean Km of 8.3  .7 and a Vmax of
demonstrated to be able to produce protein in renal399  18 in three studies. This indicates that a high
vasculature and tubular cells, but provide only transientplasma level of AGA would likely be needed to allow
expression, and trigger a significant immune responseoptimal uptake by renal epithelial cells from either cell
[10], and the overall safety of adenovirus is currentlysurface.
being addressed.
The human parvovirus adeno-associated virus type 2
DISCUSSION (AAV) has many features that make it an ideal vector for
These studies in well-differentiated tubule epithelial gene delivery to the kidney. Recombinant AAV vectors
cells indicate that, at high concentrations, AGA is trans- express no viral genes, which makes them safer and per-
ported into kidney cells from both the luminal and baso- haps less immunogenic than other vectors [11]. AAV
lateral surfaces. Uptake is greater from the basolateral vectors do not activate cell-mediated immunity that
(blood) side of the cells. Unexpectedly, the M6-P trans- would abrogate their benefit. These vectors transduce
porter appears to be active only on the bath side of dividing and nondividing cells and both wild-type and
NHCT cells in the kidney. This would indicate that other recombinant AAV integrate into the host chromosome,
mechanisms may be responsible for uptake of AGA be- resulting in long-term gene expression [12]. The humoral
yond the previously assumed M6-P receptor pathway. immune response to the AAV vector has not been shown
The kinetic data obtained in these studies suggest a po- to limit expression of the gene, as demonstrated by the
tential explanation for the inability of the adenoviral prolonged expression of recombinant factor IX intro-
gene therapy vector expressing AGA to treat completely duced by AAV in hemophiliac dogs [13]. Finally, AAV
the renal phenotype in knockout mice. The high Km has not been associated with any disease in humans. For
from both luminal and basolateral sides suggests that these reasons, AAV has clear benefit over other viral
the treated animals failed to achieve high enough levels and nonviral vectors in gene therapy. The kidney would
of AGA for optimal uptake by renal cells because of a be an ideal target organ for AAV gene therapy. In our
relatively low affinity for the protein. The inability to previous studies, it has been shown that AAV has a
achieve high enough levels of AGA to reverse the renal broad tropism for renal cells, including mesangial, proxi-
phenotype by adenoviral gene therapy indicates that lo- mal tubule, thick ascending limb, collecting tubule, and
cal gene delivery to the kidney may be a required adjunct renal cell carcinoma cells in primary culture. In vivo,
to systemic gene delivery. AAV vectors transduce tubular epithelial cells following
A number of vectors have been employed over the intraparenchymal administration [12, 14]. In addition,
last few years to convey genetic material to the kidney. reporter genes are expressed in the collecting tubule and
Most have been found to be lacking for a number of corticomedullary junction for over one year following
intraureteral injection (abstract; Lipkowitz et al, J Amreasons. Liposomally complexed DNA provides only
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A deficient mice: A model of Fabry disease. Proc Natl Acad SciSoc Nephrol 10:447A, 1999). In future studies, we hope to
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